Vas Narasimhan, Novartis CEO (Thibault Camus/AP Images)
March 26, 2021 09:44 AM EDTUpdated 11:19 AM
Pharma

No­var­tis push­es back on chair­man's 'i­nac­cu­rate and in­con­sis­ten­t' com­ments un­der­min­ing bribery set­tle­ment

Kyle Blankenship

Look­ing to move on from his com­pa­ny’s trou­bled past, No­var­tis CEO Vas Narasimhan gave the green light to a $628 mil­lion set­tle­ment in Ju­ly to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times